A breath of not so fresh air...

João Pinto Pereira, Philippe Hantson, Thierry Pieters, Matveï Apraxine and Antoine Froidure

1Pulmonology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 2Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium. 3Louvain Centre for Toxicology and Applied Pharmacology, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium. 4Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium.

Corresponding author: João Pinto Pereira (joao.pinto@saintluc.uclouvain.be)

Shareable abstract (@ERSpublications)
Despite being widely used as a recreational drug, “poppers” lack a legal framework for their delivery. Their composition may vary largely. This report describes a case of severe bronchiolitis following amyl nitrite mixture inhalation. https://bit.ly/3p3S7LM

Cite this article as: Pinto Pereira J, Hantson P, Pieters T, et al. A breath of not so fresh air... Breathe 2022; 18: 220026 [DOI: 10.1183/20734735.0026-2022].

A 23-year-old woman presented to the emergency department with acute onset respiratory symptoms consisting of chest discomfort, breathlessness and dry cough. She had no relevant past medical history, did not take any medication and did not smoke tobacco or cannabis.

This was her second visit to the emergency department with the same complaints. On her first visit, earlier that day, the patient had a normal physical examination and chest radiograph. Fit for discharge, the patient was sent home while waiting for her severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result.

On the second hospital admission, the patient had a normal lung auscultation contrasting with a transcutaneous oxygen saturation ($S_{\text{O}_2}$) of only 91% on room air. Her respiratory rate was 20 breaths per min, her heart rate was 100 beats per min and her axillary temperature 36.0°C.

Initial work-up revealed mild inflammation (C-reactive protein (CRP) 35.3 mg·dL$^{-1}$, with a normal value <5), with a leukocyte count of $6.01 \times 10^{3}$ per µL, eosinophil count of $0.37 \times 10^{3}$ per µL and D-dimer value of 431 ng·mL$^{-1}$. The nasopharyngeal PCR testing for SARS-CoV-2 RNA was negative. Results of arterial blood gases analysis are displayed in (table 1).

A high-resolution computed tomography (HRCT) without contrast enhancement was performed (figure 1).

| Parameter                        | Patient value | Normal range |
|----------------------------------|---------------|--------------|
| pH                               | 7.40          | 7.35–7.45    |
| Carbon dioxide tension, mmHg     | 36            | 35–45        |
| Oxygen tension, mmHg             | 66            | 85–95        |
| HCO$_3^-$, mmol·L$^{-1}$         | 22            | 22–28        |
| Oxyhaemoglobin, %                | 90.9          | 70–100       |
| Methaemoglobin, %                | 0.2           | 0.0–2.0      |
| Lactate, mmol·L$^{-1}$           | 0.7           | 0.5–2.2      |
After further enquiry, our patient reluctantly reported a dozen inhalations of a recreational drug, commonly known as “poppers”, the night prior to her admission (figure 2).
Pulmonary function tests (figure 3 and table 2) revealed a mixed ventilatory defect with a forced expiratory volume in the first second (FEV1) of 1 L (28% of predicted value) and a total lung capacity (TLC) of 3.61 L (68% of predicted value). Forced vital capacity was of 1.6 L (39%). Residual volume/TLC ratio was 206% of the predicted value. Obstruction was reversible following bronchodilation (administration of salbutamol 400 μg). Fractional exhaled nitric oxide (FENO) was within normal range.

The diagnosis of acute toxic bronchiolitis was established based on clinical signs, HRCT pattern and pulmonary function tests.

A bronchoscopy failed to reveal any endobronchial anomalies. Bronchoalveolar lavage composition presented a high eosinophil count (28%), along with 36% macrophages, 21% lymphocytes, 13% neutrophils and 2% epithelial cells. Endobronchial biopsies demonstrated eosinophilic infiltration in the mucosae.

Task 3
How would you treat this patient?

A short course of oral methylprednisolone (32 mg for 5 days) resulted in progressive clinical improvement. On the fifth day of her stay, our patient’s clinical state had already greatly improved and the patient was discharged the next day (figure 4 and table 3).
Task 4
If a toxic origin is suspected, which substances could be responsible for respiratory effects after “poppers” use?
   a) Isomers of amyl nitrite
   b) Diacetyl
   c) Derivatives of butanol
   d) Nitrous oxide
   e) Nitrogen dioxide

Discussion
Bronchiolitis seldom affects adults and is most often seen in younger patients following a viral infection [1]. At older ages, viral infections remain the most common aetiology along with inhalational injuries. Although many different categorisations have been proposed [2–5], no consensual classification exists today.

The equivocal term bronchiolitis encompasses many different disease processes (table 4) [6, 7]. The timeframe is also very variable: some aetiological agents will induce an acute or chronic disease, or even both.

Usually, bronchiolitis will be responsible for dry cough and breathlessness. Other typical symptoms include chest discomfort and haemoptysis. Lung function tests will usually show non-reversible obstruction, hyperinflation and diffusing capacity of the lung for carbon monoxide ($D_{LCO}$) reduction, although restrictive, mixed or reversible defects are not unusual [12]. Radiologists confronted with bronchiolitis will frequently describe features such as mosaic pattern secondary to air trapping, bronchial wall thickening, centrilobular nodules, branching linear opacities and bronchiolar dilatation [5, 13]. A lung biopsy might help obtain a definitive diagnosis, but once again, pathological findings are nonspecific and
ill-defined. They usually consist of inflammatory changes such as peribronchiolar mononuclear infiltrates, fibrosis, broncho- and bronchiolectasies [14].

Concerning the clinical case described here, there is an obvious history of toxic exposure preceding hospital admission. The low blood eosinophil count along with the favourable clinical response to corticosteroids does not fit the alternative diagnosis of eosinophilic bronchiolitis. We excluded other differential diagnoses by means of serological tests, autoimmune serologies, transbronchial biopsy, cultures and respiratory panel multiplex in the bronchoalveolar lavage fluid.

One of the most infamous toxic-related bronchiolitis is an occupational condition called silo-filler’s disease. First described as early as in the 1800s, it results from the inhalation of nitrogen dioxide (NO₂). NO₂ starts building up a few hours after the silo is filled and can reach levels of 200–2000 ppm. When in contact with water, NO₂ turns into the corrosive nitrous acid. Its inhalation can result in acute, permanent and/or even life-threatening injury. Some cases of chronic exposure resulting in bronchiolitis obliterans have also been reported [5, 14–16]. NO₂ toxicity has also been described in other settings such as in poorly ventilated combustion areas or indoor ice rinks [17].

Contrasting with the toxicity of inorganic nitrogen inhalation, exposure to organic derivatives appears less directly toxic for the lungs. As there is no legal framework for their delivery, the composition of “poppers” may vary largely. They belong to the family of aliphatic or cyclic alkyl nitrites. Usually, they are based on amyl, isopropyl or butyl nitrates. Although some moderate irritating effects could be observed on the eye, skin or lung, inhalation of “poppers” is almost never associated with lung toxicity, and not with bronchiolitis obliterans. Accidental aspiration of liquid amyl or butyl nitrite has caused lipoid pneumonia [18]. Methaemoglobinaemia is a possible complication of “poppers” inhalation but might be difficult to detect after a significant delay, such as in the present observation.

Also of note, another component was mentioned on the “poppers” bottle brought by the patient: 3-methyl-1-butanol (3MB), a microbial volatile organic compound (MVOC), that could be considered as a mild irritant. The fact that the patient reported no nasal or eye irritation reduces the likelihood of a 3MB toxicity [19].

Recently, outbreaks of e-cigarette or vaping use-associated lung injury (EVALI) have brought toxic inhalations back into the medical community spotlight. The umbrella term EVALI encompasses very distinct pathological and radiographic features (e.g. diffuse alveolar damage, acute eosinophilic pneumonia, lipoid pneumonia) [18, 20, 21].

As of today, no single trigger has been identified as being a sufficient condition for the occurrence of such a disorder, although some suspicion exists regarding the use of products such as vitamin E acetate, medium chain triglycerides, heavy metals and tetrahydrocannabinol [21, 22]. Criteria for the diagnosis of EVALI usually include the presence of constitutional or gastrointestinal symptoms that were absent in our clinical picture.

### Table 4: Disease processes encompassed by the term bronchiolitis

| Infectious | Toxic | Autoimmune | Cryptogenic/miscellaneous |
|------------|-------|------------|--------------------------|
| Respiratory viruses, such as the respiratory syncytial virus, influenza and parainfluenza | Smoke-related and e-cigarette or vaping use-associated lung injury (EVALI) | Bronchiolitis obliterans syndrome (BOS) seen in chronic lung allograft dysfunction | Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) |
| Parasitic | Diffuse aspiration bronchiolitis | Sjögren syndrome | Langerhans histiocytosis |
| Fungal | Nitrogen dioxide (NO₂) inhalation | Paraneoplastic | Follicular bronchiolitis |
| Mycobacterial | Mustard gas (sulfur mustard) | Rheumatoid arthritis | Panbronchiolitis |
| Mycoplasma pneumoniae | Ingestion of *Sauropus androgynus* | Systemic lupus erythematosus | Eosinophilic bronchiolitis |
| Allergic bronchopulmonary mycosis | Diacetyl (popcorn plant workers) | Inflammatory bowel disease-related bronchiolitis | COPA syndrome |

Information from [8–11].
The scientific evidence supporting specific treatment of toxic inhalations is disappointing and at best provided by some case series. Corticosteroids seem to be the only effective treatment against nitrogen dioxide exposure with clinical, functional and radiological partial or full recovery [23, 24]. The timing and the dose of the glucocorticoid administration is not standardised although it is hypothesised that an early administration reduces the risk of further complications [24]. This beneficial effect of glucocorticoids does not seem as spectacular in other exposure-related lung diseases, such as inhalation of diacetyl seen in popcorn plant workers, textile workers suffering from Ardysil syndrome [25, 26] or inhalation of mustard gas [20]. Other therapies for inhalational bronchiolitis have been investigated such as N-acetyl cysteine, cyclophosphamide, azithromycin and bronchodilators with no strong proof of a beneficial effect.

Regardless of the aetiologic agent, the severity of the inhalational injury seems dose-related, thus exposure cessation is essential. Supportive treatment should also be provided. Lung transplantation remains as a last line of treatment in cases of severe respiratory insufficiency.

After an empiric treatment by methylprednisolone, our patient presents a full recovery. No relapse occurred on follow-up.

**Answer 1**
The chest CT scan revealed some nonspecific findings of multiple micronodules such as the one that can be seen in the right upper quadrant of the image; diffuse bronchial wall thickening (figure 1a), hyperinflation and the presence of endobronchial impactions.

**Answer 2**
The clinical and radiological picture is compatible with an acute bronchiolitis, a nonspecific term used to describe the inflammation and the resulting airflow obstruction of small airways. The most common aetiologic agents in adults are viral infections and inhalational exposure.

**Answer 3**
Exposure cessation is essential. Supportive care such as oxygen therapy should be provided in case of hypoxaemia. Based on a previous case series in the literature, treatment with methylprednisolone was initiated.

**Answer 4**
Correct answers: a and c. As the exact composition of “poppers” may vary, users are mainly exposed to isomers of amyl nitrite and to some organic solvents (e.g. butanol derivatives). “Poppers” may be a source of nitrous oxide and caution should be exerted with medications using this pathway.

Conflict of interest: None declared.

References
1 Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. *Lancet* 2017; 389: 211–224.
2 Myers JL, Colby TV. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. *Clin Chest Med* 1993; 14: 611–622.
3 Katzenstein A-L. Miscellaneous II: nonspecific inflammatory and destructive diseases. In: Katzenstein and Askin’s Surgical Pathology of Non-Neoplastic Lung Disease. 4th Edn. Philadelphia, Elsevier, 2006.
4 Cagle PT, Allen TC, Beasley MB, eds. Diagnostic Pulmonary Pathology. 2nd Edn. New York, Informa, 2008.
5 Banks DE, Morris MJ. Inhalational constrictive bronchiolitis: the evolution of our understanding of this disease. *Lung* 2021; 199: 32–334.
6 Ryu JH. Classification and approach to bronchiolar diseases. *Curr Opin Pulm Med* 2006; 12: 145–151.
7 Ryu JH, Azadeh N, Samhouri B, et al. Recent advances in the understanding of bronchiolitis in adults. *F1000Res* 2020; 9: F1000.
8 Lai RS, Chiang AA, Wu MT, et al. Outbreak of bronchiolitis obliterans associated with consumption of *Sauropus androgynus* in Taiwan. *Lancet* 1996; 348: 83–85.

https://doi.org/10.1183/20734735.0026-2022
Allen TC. Pathology of small airways disease. Arch Pathol Lab Med 2010; 134: 702–718.

Sun TY, Hwang G, Pancirer D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. Eur Respir J 2022; 59: 2101058.

Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277–1292.

King TE Jr. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med 2003; 24: 567–576.

Winningham PJ, Martínez-Jiménez S, Rosado-de-Christenson ML, et al. Bronchiolitis: a practical approach for the general radiologist. Radiographics 2017; 37: 777–794.

Visscher DW, Myers JL. Bronchiolitis: the pathologist’s perspective. Proc Am Thorac Soc 2006; 3: 41–47.

Ravaglia C, Poletti V. Bronchiolitis and bronchiolar disorders. Semin Respir Crit Care Med 2020; 41: 311–332.

Krefft SD, Cool CD, Rose CS. The emerging spectrum of exposure-related bronchiolitis. Curr Opin Allergy Clin Immunol 2018; 18: 87–95.

Brauer M, Spengler JD. Nitrogen dioxide exposures inside ice skating rinks. Am J Public Health 1994; 84: 429–433.

Hagan IG, Burney K. Radiology of recreational drug abuse. Radiographics 2007; 27: 919–940.

Ernstgård L, Norbäck D, Nordquist T, et al. Acute effects of exposure to vapors of 3-methyl-1-butanol in humans. Indoor Air 2013; 23: 227–235.

Ghanei M, Khalili AR, Arab MJ, et al. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol 2005; 97: 302–305.

Butt YM, Smith ML, Tazelaar HD, et al. Pathology of vaping-associated lung injury. N Engl J Med 2019; 381: 1780–1781.

Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin – final report. N Engl J Med 2020; 382: 903–916.

Tse RL, Bockman AA. Nitrogen dioxide toxicity. Report of four cases in firemen. JAMA 1970; 212: 1341–1344.

Douglas WW, Hepper NG, Colby TV. Silo-filler’s disease. Mayo Clin Proc 1989; 64: 291–304.

Akpinar-Elci M, Travis WD, Lynch DA, et al. Bronchiolitis obliterans syndrome in popcorn production plant workers. Eur Respir J 2004; 24: 298–302.

Romero S, Hernández L, Gil J, et al. Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J 1998; 11: 265–271.